$435 Million is the total value of Cormorant Asset Management, LP's 46 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 89.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVN | Buy | MEDIVATION INC | $38,622,000 | +10.7% | 600,000 | +9.7% | 8.88% | -12.3% |
| CBST | Sell | CUBIST PHARMACEUTICALS INC | $21,945,000 | -20.3% | 300,000 | -25.0% | 5.05% | -36.9% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $21,609,000 | +4.4% | 207,500 | +3.8% | 4.97% | -17.3% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $20,463,000 | +190.9% | 300,000 | +200.0% | 4.70% | +130.4% |
| RCPT | Buy | RECEPTOS INC | $18,873,000 | +86.0% | 450,000 | +28.6% | 4.34% | +47.4% |
| DYAX | Sell | DYAX CORP | $17,960,000 | -16.4% | 2,000,000 | -29.8% | 4.13% | -33.7% |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $16,490,000 | – | 50,000 | +100.0% | 3.79% | – |
| ARWR | Buy | ARROWHEAD RESEARCH CORP | $16,420,000 | +52.0% | 1,000,000 | +0.5% | 3.78% | +20.4% |
| IDIX | Sell | IDENIX PHARMACEUTICALS INC | $15,075,000 | -13.8% | 2,500,000 | -14.5% | 3.47% | -31.7% |
| PTCT | Buy | PTC THERAPEUTICS INC | $14,377,000 | +2840.1% | 550,000 | +1809.7% | 3.31% | +2228.2% |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $13,868,000 | – | 100,000 | +100.0% | 3.19% | – |
| PRTA | New | PROTHENA CORP PLC | $13,409,000 | – | 350,000 | +100.0% | 3.08% | – |
| DXCM | DEXCOM INC | $12,408,000 | +16.8% | 300,000 | 0.0% | 2.85% | -7.5% | |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $12,357,000 | +506.6% | 1,168,000 | +335.8% | 2.84% | +380.7% |
| MRK | New | MERCK & CO. INC NEW | $11,354,000 | – | 200,000 | +100.0% | 2.61% | – |
| SGMO | Buy | SANGAMO BIOSCIENCES INC | $10,848,000 | +369.8% | 600,000 | +261.0% | 2.49% | +272.2% |
| ACRX | ACELRX PHARMACEUTICALS INC | $9,008,000 | +6.2% | 750,000 | 0.0% | 2.07% | -15.9% | |
| SRNE | New | SORRENTO THERAPEUTICS INC | $8,974,000 | – | 700,000 | +100.0% | 2.06% | – |
| TSRO | TESARO INC | $8,844,000 | +4.4% | 300,000 | 0.0% | 2.03% | -17.3% | |
| ALKS | New | ALKERMES PLC | $8,818,000 | – | 200,000 | +100.0% | 2.03% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $8,649,000 | +277.4% | 280,000 | +180.0% | 1.99% | +199.1% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $8,312,000 | +15.6% | 120,000 | +0.6% | 1.91% | -8.4% |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $8,260,000 | – | 400,000 | +100.0% | 1.90% | – |
| ARRY | ARRAY BIOPHARMA INC | $8,225,000 | -6.2% | 1,750,000 | 0.0% | 1.89% | -25.7% | |
| GLYC | New | GLYCOMIMETICS INC | $7,665,000 | – | 469,400 | +100.0% | 1.76% | – |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $7,299,000 | -63.5% | 300,000 | -62.5% | 1.68% | -71.1% |
| CMRX | Buy | CHIMERIX INC | $6,852,000 | +217.1% | 300,000 | +109.8% | 1.58% | +151.4% |
| OMER | New | OMEROS CORP | $6,035,000 | – | 500,000 | +100.0% | 1.39% | – |
| GALT | New | GALECTIN THERAPEUTICS INC | $5,328,000 | – | 348,000 | +100.0% | 1.22% | – |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $5,180,000 | +168.3% | 200,000 | +166.7% | 1.19% | +112.7% |
| EGRX | New | EAGLE PHARMACEUTICALS INC | $5,100,000 | – | 400,000 | +100.0% | 1.17% | – |
| RMTI | New | ROCKWELL MED INC | $5,064,000 | – | 400,000 | +100.0% | 1.16% | – |
| NVAX | NOVAVAX INC | $4,530,000 | -11.5% | 1,000,000 | 0.0% | 1.04% | -29.9% | |
| REPH | New | RECRO PHARMA INC | $3,660,000 | – | 500,000 | +100.0% | 0.84% | – |
| GNVC | New | GENVEC INC | $3,523,000 | – | 1,329,300 | +100.0% | 0.81% | – |
| PCRX | PACIRA PHARMACEUTICALS INC | $3,500,000 | +21.7% | 50,000 | 0.0% | 0.80% | -3.5% | |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $3,357,000 | -79.1% | 50,000 | -80.0% | 0.77% | -83.5% |
| AGEN | New | AGENUS INC | $3,170,000 | – | 1,000,000 | +100.0% | 0.73% | – |
| AQXP | New | AQUINOX PHARMACEUTICALS INC | $3,143,000 | – | 246,877 | +100.0% | 0.72% | – |
| GERN | Sell | GERON CORP | $3,135,000 | -80.5% | 1,500,000 | -55.8% | 0.72% | -84.6% |
| ASPX | New | AUSPEX PHARMACEUTICALS INC | $3,076,000 | – | 100,000 | +100.0% | 0.71% | – |
| BIIB | New | BIOGEN IDEC INC | $3,059,000 | – | 10,000 | +100.0% | 0.70% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $2,933,000 | – | 60,000 | +100.0% | 0.67% | – |
| RGLS | Buy | REGULUS THERAPEUTICS INC | $1,804,000 | +144.1% | 200,000 | +100.0% | 0.42% | +93.9% |
| IDRA | New | IDERA PHARMACEUTICALS INC | $1,632,000 | – | 400,000 | +100.0% | 0.38% | – |
| CLTX | New | CELSUS THERAPEUTICS PLCsponsored adr ne | $668,000 | – | 103,000 | +100.0% | 0.15% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -10,000 | -100.0% | -0.08% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -0.10% | – |
| DNDNQ | Exit | DENDREON CORP | $0 | – | -150,000 | -100.0% | -0.13% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -27,700 | -100.0% | -0.14% | – |
| XNPT | Exit | XENOPORT INC | $0 | – | -200,000 | -100.0% | -0.33% | – |
| OSIR | Exit | OSIRIS THERAPEUTICS INC NEW | $0 | – | -107,800 | -100.0% | -0.50% | – |
| PODD | Exit | INSULET CORP | $0 | – | -150,000 | -100.0% | -1.62% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS INC | $0 | – | -250,000 | -100.0% | -1.76% | – |
| Exit | ALKERMES PLC | $0 | – | -150,000 | -100.0% | -1.77% | – | |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -270,000 | -100.0% | -4.16% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -120,000 | -100.0% | -5.88% | – |
| KERX | Exit | KERYX BIOPHARMACEUTICALS | $0 | – | -1,700,000 | -100.0% | -6.39% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.